“Targeting the Inactivation of the MYC Oncogene to Treat Osteogenic Sarcoma”
We have found that even brief inactivation of the MYC oncogene can result in sustained regression of osteogenic sarcoma (Jain et al, Science, 2002; also see accompanying review Weinstein, Science, 2002). Now, we propose to perform several pre-clinical studies to evaluate the effectiveness of a novel anti-sense approach for the inactivation of MYC for the treatment of osteogenic sarcoma. We will evaluate the mechanisms by which brief inactivation of MYC induces tumor regression through cDNA microarrays. From these experiments, we will obtain the preliminary results necessary to subsequently conduct a clinical trial to evaluate the effectiveness of the inactivation of MYC to treat human osteogenic sarcoma.